Bioptik Technology Incorporation (4161) Fair Value & Analysis
Healthcare · TW · Market cap 1.4B TWD
Fair value as of: Jun 24, 2026
Analysis
Bioptik Technology Incorporation (4161) currently trades at 23.10 TWD, while our model-based Fair Value estimate is 21.44 TWD — implying the stock looks roughly 7.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also provides dietary supplements, such as capsules, gel capsules, tablets, solutions, powder sachet, jelly, and gummy; cosmetic products, including sunscreen, cream/lotion, make-up removal, shampoo, time capsule, and toner/essence; and skin care products. In addition, the company is involved in manufacturing feed, canned food, and food additive, aircraft and parts, and chemicals; wholesale and import and export trade of cosmetics raw materials, semi-finished products and finished products; cosmetics retail and wholesale; and special forestry management. Bioptik Technology Incorporation was founde…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Bioptik Technology Incorporation (4161) undervalued?
What is the fair value of 4161?
What is the quality score of 4161?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.